2 documents found, page 1 of 1
Prolonged-release fampridine in multiple sclerosis: clinical data and real-worl...
Albrecht, P; Bjørnå, K; Brassat, D; Farrell, R; Feys, P; Hobart, J; Hupperts, R; Linnebank, M; Magdič, J; Oreja-Guevara, C; Pozzilli, C; Salgado, AVProlonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient...
Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in...
Hupperts, R; Becker, V; Friedrich, J; Gobbi, C; Salgado, AV; Sperling, B; You, XOBJECTIVES: The 12-month observational PERSIST study (NCT01405872) evaluated adherence associated with the intramuscular IFNβ-1a (i.m. IFN-β-1a) autoinjector pen in multiple sclerosis (MS) patients. METHODS: MS patients initiating i.m. IFN-β-1a autoinjector treatment were prospectively assessed for physician-reported persistence (percentage of patients remaining on therapy) and patient-reported outcomes, includ...